The Real Reason Life-Saving Drugs Took Decades to Reach Us
Learn how Prospera’s insurance-backed regulatory model is slashing the cost and time to bring new therapies to market—from $300M to just $300K—and why this free city is attracting high-agency founders from around the world.
In this episode of DeSci Pilled, Ryan explores the bold experiment of Prospera—a private charter city in Roatán, Honduras—with guests Lonis Hamaili, VP of Growth at Prospera, Niklas Anzinger, founder of Infinita VC and Zoe Isabel Senón, founder of Aevitas House. They discuss how Prospera is flipping the script on regulation, creating a haven for biotech, longevity research, and crypto innovation.
Watch the episode.